Images
Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.
Link to Agencia SINC
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
